莫西沙星及其他氟喹诺酮类药物对肺炎支原体的体外活性
In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
作者信息
Hamamoto K, Shimizu T, Fujimoto N, Zhang Y, Arai S
机构信息
Department of Bacteriology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan.
出版信息
Antimicrob Agents Chemother. 2001 Jun;45(6):1908-10. doi: 10.1128/AAC.45.6.1908-1910.2001.
Abstract
A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC(50) and MBC(50)) and 0.3 microg/ml (MIC(90) and MBC(90)) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.
摘要
对总共105株肺炎支原体分离株进行了对莫西沙星、司帕沙星、左氧氟沙星和环丙沙星的敏感性评估。新合成的化合物莫西沙星显示出最大活性。使50%和90%分离株受到影响的MIC和MBC分别为0.15（MIC(50)和MBC(50)）和0.3微克/毫升（MIC(90)和MBC(90)）。结果表明莫西沙星可能是一种有前景的抗支原体药物。
相似文献
1
In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
Antimicrob Agents Chemother. 2001 Jun;45(6):1908-10. doi: 10.1128/AAC.45.6.1908-1910.2001.
2
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
J Antimicrob Chemother. 2006 Nov;58(5):960-5. doi: 10.1093/jac/dkl356. Epub 2006 Aug 26.
3
In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
J Microbiol Immunol Infect. 2001 Sep;34(3):178-84.
4
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Int J Antimicrob Agents. 2005 Feb;25(2):163-7. doi: 10.1016/j.ijantimicag.2004.08.017.
5
Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae.
Int J Antimicrob Agents. 2003 Jun;21(6):574-7. doi: 10.1016/s0924-8579(03)00060-8.
6
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
J Antimicrob Chemother. 2001 Jun;47(6):875-7. doi: 10.1093/jac/47.6.875.
7
Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae.
J Antimicrob Chemother. 1998 Dec;42(6):803-6. doi: 10.1093/jac/42.6.803.
8
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
J Antimicrob Chemother. 2009 May;63(5):886-94. doi: 10.1093/jac/dkp057. Epub 2009 Mar 11.
9
In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
J Infect Chemother. 2002 Mar;8(1):115-7. doi: 10.1007/s101560200019.
10
Bactericidal activity of moxifloxacin against pneumococci.
Clin Microbiol Infect. 2001 Jan;7(1):47-8.
引用本文的文献
1
Antimicrobial Resistance in spp.
Microbiol Spectr. 2018 Jul;6(4). doi: 10.1128/microbiolspec.ARBA-0030-2018.
2
Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data.
BMC Infect Dis. 2015 Apr 25;15:197. doi: 10.1186/s12879-015-0933-9.
3
Mycoplasma pneumonia: Clinical features and management.
Lung India. 2010 Apr;27(2):75-85. doi: 10.4103/0970-2113.63611.
4
Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR.
Antimicrob Agents Chemother. 2005 Dec;49(12):4993-8. doi: 10.1128/AAC.49.12.4993-4998.2005.
5
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Dec;47(12):3973-5. doi: 10.1128/AAC.47.12.3973-3975.2003.
6
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
本文引用的文献
1
In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Antimicrob Agents Chemother. 1997 Jul;41(7):1594-7. doi: 10.1128/AAC.41.7.1594.
2
Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
Antimicrob Agents Chemother. 1997 Jun;41(6):1377-9. doi: 10.1128/AAC.41.6.1377.
3
Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
Antimicrob Agents Chemother. 1993 Feb;37(2):287-92. doi: 10.1128/AAC.37.2.287.
4
In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
Antimicrob Agents Chemother. 1993 Sep;37(9):1826-30. doi: 10.1128/AAC.37.9.1826.
5
Method of reliable determination of minimal lethal antibiotic concentrations.
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
6
Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics.
J Pediatr. 1970 Mar;76(3):438-43. doi: 10.1016/s0022-3476(70)80485-1.
7
Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria.
Rev Infect Dis. 1986 Jul-Aug;8 Suppl 3:S279-91. doi: 10.1093/clinids/8.supplement_3.s279.
8
In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
Antimicrob Agents Chemother. 1988 Oct;32(10):1500-2. doi: 10.1128/AAC.32.10.1500.
9
Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.
Diagn Microbiol Infect Dis. 1989 Sep-Oct;12(5):433-5. doi: 10.1016/0732-8893(89)90115-6.
Zotero 插件